Abstract
The ability of B cells to function as tolerogenic antigen presenting cells (APCs) in vitro and in vivo, makes them ideal targets for gene therapy strategies focused on the induction and re-establishment of tolerance. Current therapy methods employ retroviral vectors for infection of B cells or bone marrow cells and subsequent expression of the target antigen. Moreover, the efficacy of peptide-IgG fusion constructs which take advantage of the tolerogenic properties of IgG has been demonstrated. In this review, we discuss gene therapy approaches mediated by B cells and bone marrow cells for tolerance acquisition in various mouse models for autoimmune disease, hemophilia and transplantation. The results indicate that gene therapy strategies successfully reduce the incidence of disease, or delay disease onset in multiple mouse models for autoimmune disease and hemophilia. Additionally, gene therapy has proven effective in a mouse transplantation model. While these studies show great promise, the mechanisms involved in tolerance, including the role of regulatory T cells, will need to be more clearly defined before the transition to a clinical setting can occur.
Keywords: tolerance, B cells, gene therapy, immunoglobulin fusions, retroviral vector, antigen presentation, autoimmunity, hemophilia, transplantation, bone marrow cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: B-Cell Based Gene Therapy for Inducing Tolerance
Volume: 6 Issue: 2
Author(s): Indira Carey, Yan Su, Yufei Jiang, Jonathan Skupsky and David W. Scott
Affiliation:
Keywords: tolerance, B cells, gene therapy, immunoglobulin fusions, retroviral vector, antigen presentation, autoimmunity, hemophilia, transplantation, bone marrow cells
Abstract: The ability of B cells to function as tolerogenic antigen presenting cells (APCs) in vitro and in vivo, makes them ideal targets for gene therapy strategies focused on the induction and re-establishment of tolerance. Current therapy methods employ retroviral vectors for infection of B cells or bone marrow cells and subsequent expression of the target antigen. Moreover, the efficacy of peptide-IgG fusion constructs which take advantage of the tolerogenic properties of IgG has been demonstrated. In this review, we discuss gene therapy approaches mediated by B cells and bone marrow cells for tolerance acquisition in various mouse models for autoimmune disease, hemophilia and transplantation. The results indicate that gene therapy strategies successfully reduce the incidence of disease, or delay disease onset in multiple mouse models for autoimmune disease and hemophilia. Additionally, gene therapy has proven effective in a mouse transplantation model. While these studies show great promise, the mechanisms involved in tolerance, including the role of regulatory T cells, will need to be more clearly defined before the transition to a clinical setting can occur.
Export Options
About this article
Cite this article as:
Carey Indira, Su Yan, Jiang Yufei, Skupsky Jonathan and Scott W. David, B-Cell Based Gene Therapy for Inducing Tolerance, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (2) . https://dx.doi.org/10.2174/187152307780598072
DOI https://dx.doi.org/10.2174/187152307780598072 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders
Current Molecular Pharmacology Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases
Current Pharmaceutical Design Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine The Role of Mitochondria in Systemic Lupus Erythematosus: A Glimpse of Various Pathogenetic Mechanisms
Current Medicinal Chemistry Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Current Pharmaceutical Design Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis
Current Pharmaceutical Design The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy Spots, Blots, Peaks and Chips: Proteomic Approaches in Autoimmune Diseases
Current Pharmaceutical Design Acquired Hemophilia as Initial Presentation in a Patient with Systemic Lupus Erythematosus
Current Rheumatology Reviews Targeting Cytokines of the Interleukin-12 Family in Autoimmunity
Current Medicinal Chemistry Some Important Dietary Polyphenolic Compounds: An Anti-inflammatory and Immunoregulatory Perspective
Mini-Reviews in Medicinal Chemistry Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design